Nikom Pharmaceutical Private Limited, a active private limited company, was established on 04 July 2003 in Mumbai, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24230MH2003PTC141173. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹2.10 M.
It upholds a compliant status. Its leadership includes Hetal Mohan Parmar (Director), Anagha Rajesh Pathak (Additional Director), Akella Subrahmanyam (Director). Past directors included Gaurav Thakkar Naresh, Jayant Shantilal Mirani, Chandrashekhar Laxman Parab. It holds ₹25.76 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 510, Keshava Building Bandra Kurla Complex, Bandra (East), Mumbai, Maharashtra, 400051.
U24230MH2003PTC141173
141173
04 July 2003
₹1.00 Cr
₹2.10 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Nikom Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hetal Mohan Parmar | Director | 04 Jul 2025 | Current |
| Anagha Rajesh Pathak | Additional Director | 17 Jul 2021 | Current |
| Akella Subrahmanyam | Director | 25 Jun 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 22 Jan 2020 | Past |
| Pramod Abcsdd | Director | 01 Jun 2019 | Past |
| Pramod Abcsdd | Additional Director | 30 Dec 2020 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
| Pramod Abcsdd | Director | 25 Jun 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nikom Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 94.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.16%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Nikom Pharmaceutical had a public holding of 0.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹257,550,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2022 | Others | ₹3.50 Cr | Open |
| 18 Jun 2018 | Others | ₹2.20 M | Open |
| 19 Mar 2012 | Others | ₹22.04 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nikom Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nikom Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nikom Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Hetal Mohan Parmar was appointed as a Director was appointed as a Director on 04 Jul 2025 & has been associated with this company since 4 months 29 days . was recorded as a recent event.
Progress on Nikom Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Nikom Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was documented.
The activity A charge with Others of Rs. 3.50 Cr registered on 29 Aug 2022 with Charge ID 100606922 was modified on 27 Jun 2023. was completed.
Progress on A charge with Others amounted to Rs. 3.50 Cr with Charge ID 100606922 was registered on 29 Aug 2022. was documented.
A charge with Others of Rs. 22.04 Cr registered on 19 Mar 2012 with Charge ID 10354260 was modified on 20 Nov 2021. was recorded as a recent event.
The CIN of Nikom Pharmaceutical Private Limited is U24230MH2003PTC141173.
Nikom Pharmaceutical Private Limited is headquartered at 510, Keshava Building Bandra Kurla Complex, Bandra (East), Mumbai, Maharashtra, 400051.
Nikom Pharmaceutical Private Limited was incorporated on 04 July 2003.
The current directors of Nikom Pharmaceutical Private Limited are
The primary industry of Nikom Pharmaceutical Private Limited is Trade.
Nikom Pharmaceutical Private Limited is unlisted.
The authorized capital of Nikom Pharmaceutical Private Limited is ₹1.00 Cr, and the paid-up capital is ₹2.10 M.
The compliance status of Nikom Pharmaceutical Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX